Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H24ClN3O2.C4H4O4 |
Molecular Weight | 489.949 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.COC1=C(C=C(Cl)C(N)=C1)C(=O)NC2CCN(CC3=CC=CC=C3)CC2
InChI
InChIKey=BCVIWCRZYPHHMQ-BTJKTKAUSA-N
InChI=1S/C20H24ClN3O2.C4H4O4/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14;5-3(6)1-2-4(7)8/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25);1-2H,(H,5,6)(H,7,8)/b;2-1-
Molecular Formula | C20H24ClN3O2 |
Molecular Weight | 373.876 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Clebopride is a dopamine antagonist drug. It is used to treat functional gastrointestinal disorder such as nausea or vomiting. Unchanged parent drug was the most abundant compound in human urine. Major metabolites included the hydroxylation at benzyl group to yield carbinolamine and its further N-dealkylation product, and the piperidine ring hydroxylation/oxidation metabolite (a lactam).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14871277 |
2.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLEBOPRIDE Approved UseClebopride is used in the treatment of stomach ulcer, inflammation of stomach and intestine, indigestion. It also reduces the symptoms like excessive air accumulation in gut, nausea and vomiting associated with stomach discomfort. |
PubMed
Title | Date | PubMed |
---|---|---|
[Drug-induced extrapyramidal syndrome. Apropos of 22 cases]. | 1987 Feb |
|
Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. | 2007 Mar |
|
Effects of vehicles and enhancers on transdermal delivery of clebopride. | 2007 Sep |
|
Acute oculogyric crisis in a patient taking clebopride. | 2008 |
|
Acute hemifacial dystonia possibly induced by clebopride. | 2009 Mar-Apr |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17365143
Clebopride at 10 uM significantly decreased the Vmax of phase 0 depolarization in isolated rabbit Purkinje fiber and significantly prolonged the action potential duration at 90% repolarization, whereas the action potential duration at 50% repolarization was not prolonged. For hERG potassium channel currents in human ether-à-go-go-related gene (hERG)-stably transfected Chinese hamster ovarian (CHO) cells the IC50 value was 0.62 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:59:10 UTC 2023
by
admin
on
Fri Dec 15 16:59:10 UTC 2023
|
Record UNII |
P42041X5SU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB01334MIG
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY | |||
|
236701
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY | RxNorm | ||
|
6420010
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY | |||
|
100000087947
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY | |||
|
DTXSID6047787
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY | |||
|
P42041X5SU
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY | |||
|
C014417
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY | |||
|
84370-95-6
Created by
admin on Fri Dec 15 16:59:10 UTC 2023 , Edited by admin on Fri Dec 15 16:59:10 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |